Seeking New Opportunities For Traditional Chinese Medicine
This article was originally published in PharmAsia News
Executive Summary
A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.
You may also be interested in...
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
The Coartem Story: Novartis Workers In NY Feel Uplift In Battling Malaria
On New Year's Eve in 2005, the operators of Novartis' plant in Suffern, N.Y. were jubilant. The facility had just manufactured its 20 millionth treatment of Coartem (artemether/lumefantrine)